Abstract
Inflammatory and autophagy-related gene P62 is highly expressed in most human tumor tissues. Herein, we demonstrate that P62 promotes human mesenchymal stem cells’ malignant transformation via the cascade of P62-tumor necrosis factor alpha (TNF-α)-CUDR-CTCF-insulin growth factor II (IGFII)-H-Ras signaling. Mechanistically, we reveal P62 enhances IGFII transcriptional activity through forming IGFII promoter-enhancer chromatin loop and increasing METTL3 occupancy on IGFII 3′ UTR and enhances H-Ras overexpression by harboring inflammation-related factors, e.g., TNFR1, CLYD, EGR1, NFκB, TLR4, and PPARγ. Furthermore, the P62 cooperates with TNF-α to promote malignant transformation of mesenchymal stem cells. These findings, for the first time, provide insight into the positive role that P62 plays in malignant transformation of mesenchymal stem cells and reveal a novel link between P62 and the inflammation factors in mesenchymal stem cells.
Highlights
Mesenchymal stromal cells (MSCs) are a kind of stromal cell within the tumor microenvironment.[1]
The results showed that the interplay between METTL3 and insulin growth factor II (IGFII) mRNA probe was increased in P62-overexpressing human-bone-marrow-derived mesenchymal stem cells (HBMMSCs) (1.89 ± 0.34 versus 5.52 ± 0.53; n = 3; p = 0.009 < 0.01) and attenuated in P62 knocked down HBMMSCs compared to the corresponding control (168 ± 0.29 versus 0.31 ± 0.06; n = 3; p = 0.0075 < 0.01; Figure 4G)
We demonstrate that P62 promotes malignant differentiation of human mesenchymal stem cells via cascade of P62-tumor necrosis factor alpha (TNF-a)-CUDR-CTCF-IGFII-H-Ras signaling (Figure 9)
Summary
Mesenchymal stromal cells (MSCs) are a kind of stromal cell within the tumor microenvironment.[1]. P62 upregulation is commonly observed in human tumors and contributes directly to tumorigenesis.[4,8] Strikingly, P62 is necessary for Ras to trigger IkappaB kinase (IKK) through the polyubiquitination of tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6).[9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
